Zimmer Biomet Holdings, Inc. (ZBH): Daniel P Florin , Sr. VP, CFO of Zimmer Biomet Holdings, Inc. sold 12,000 shares on Apr 12, 2016. The Insider selling transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were sold at $110.00 per share for a total value of $1,320,000.00 according the SEC Form 4 Filing.
Company has been under the radar of several Street Analysts.Zimmer Biomet Holdings Inc is Initiated by Nomura to Buy. The Rating was issued on Mar 17, 2016.Zimmer Biomet Holdings Inc is Downgraded by Argus to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Mar 4, 2016.Zimmer Biomet Holdings Inc is Reiterated by Oppenheimer to Outperform while Lowering the Price Target of the company shares to $ 120 from a previous price target of $124 . The Rating was issued on Feb 8, 2016.Zimmer Biomet Holdings Inc is Reiterated by Needham to Buy and the brokerage firm has raised the Price Target to $ 129 from a previous price target of $127 .The Rating was issued on Jan 29, 2016.
Currently the company Insiders own 1.4% of Zimmer Biomet Holdings Inc shares according to the proxy statements.During last six month period, the net percent change held by insiders has seen a change of -5.76%.
Zimmer Biomet Holdings Inc: On Monday, Apr 11, 2016 heightened volatility was witnessed in Zimmer Biomet Holdings Inc which led to swings in the share price. The shares opened for trading at $109.06 and hit $109.71 on the upside , eventually ending the session at $109.3, with a gain of 0.31% or 0.34 points. The heightened volatility saw the trading volume jump to 13,96,002 shares. The 52-week high of the share price is $119.1 and the company has a market cap of $21,733 M . The 52-week low of the share price is at $88.27.
Zimmer Biomet Holdings Inc. formerly Zimmer Holdings Inc. is a musculoskeletal healthcare company. The Company designs manufactures and markets orthopedic reconstructive products; sports medicine biologics extremities and trauma products; spine bone healing craniomaxillofacial and thoracic products; dental implants and related surgical products. The Company manages its operations through three geographic segments: the Americas comprising principally of the United States and includes other North Central and South American markets; Europe comprising principally of Europe and includes the Middle East and African markets; and Asia Pacific comprising primarily of Japan and includes other Asian and Pacific markets. The Company markets and sells products through three channels: direct to healthcare institutions such as hospitals or direct channel accounts; through stocking distributors and healthcare dealers and directly to dental practices and dental laboratories.